Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc Analysis From the PREVENT Trial
Source: View publication →
In a post hoc analysis of the PREVENT trial, preventive percutaneous coronary intervention significantly reduced major cardiac events only in patients with near-infrared spectroscopy-defined lipid-rich plaques, showing no benefit in non-lipid-rich plaques despite high plaque burden.
Key Findings
Study Design
Study Limitations
Clinical Significance
This study demonstrates that anatomical severity alone (high plaque burden and small minimal lumen area) is insufficient to justify preventive PCI for non-flow-limiting lesions. Plaque composition—specifically the presence of a lipid-rich core identified by near-infrared spectroscopy—is a critical prerequisite for deriving benefit from preventive PCI, paving the way for targeted, image-guided precision interventions.
Historical Context
The original PREVENT trial was a landmark study showing that preventive PCI of functionally insignificant but morphologically vulnerable plaques improved outcomes over medical therapy alone. However, identifying precisely which vulnerable plaques merited intervention remained controversial. This 2026 analysis addresses that gap by highlighting the pivotal role of the lipid core burden index (LCBI) measured by near-infrared spectroscopy (NIRS), building on years of research validating NIRS as a reliable tool for detecting high-risk atherosclerotic lesions.
Guided Discussion
High-yield insights from every perspective
Based on the pathophysiology of acute coronary syndromes, why would a plaque with a large lipid core be more prone to causing major adverse cardiac events than a non-lipid-rich plaque of the exact same size and luminal narrowing?
Key Response
A large necrotic lipid core, especially when combined with a thin fibrous cap (a thin-cap fibroatheroma or TCFA), creates biomechanical instability. Upon rupture, the highly thrombogenic lipid core is exposed to the bloodstream, triggering acute thrombosis. This explains why plaque composition is a superior predictor of acute events compared to mere plaque volume or angiographic stenosis.
If you are performing a diagnostic angiogram and note a non-obstructive 50% stenosis, why is angiography alone insufficient to determine the need for preventive PCI according to this study, and what specific intravascular imaging modality is required?
Key Response
Angiography only provides a 2D silhouette of the lumen and cannot assess plaque composition or vulnerability. Near-infrared spectroscopy (NIRS), often combined with IVUS, is specifically required to detect and quantify the lipid core burden index (maxLCBI), which this study identifies as the crucial factor for determining if a plaque warrants preventive stenting.
This post hoc analysis suggests preventive PCI shows no benefit in non-lipid-rich plaques despite high plaque burden. How does this finding challenge the traditional concept that revascularization benefits patients primarily through mechanical expansion of high-burden lesions?
Key Response
Traditionally, PCI is thought to improve outcomes by relieving ischemia through luminal enlargement (burden reduction). However, this study suggests the benefit of preventive PCI in vulnerable plaques is primarily mechanical sealing or passivation of the lipid core. Stenting a high-burden, non-lipid (fibrous/calcific) plaque does not reduce events because these plaques are already mechanically stable, highlighting a shift towards composition-driven interventions.
Given these findings, should we routinely perform NIRS on all non-culprit moderate lesions during PCI for acute coronary syndrome, or does the periprocedural risk and cost outweigh the potential benefit of preventive stenting?
Key Response
While stenting lipid-rich plaques reduces future events, the attending must weigh the added procedure time, the cost of NIRS-IVUS catheters, and the risk of periprocedural MI from intervening on non-obstructive lesions against the efficacy of intensive lipid-lowering therapies (e.g., PCSK9 inhibitors). It demands highly selective patient phenotyping to avoid oculostenotic over-stenting.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
As a post-hoc analysis of the PREVENT trial, what are the primary statistical threats to validity when claiming that the treatment effect of preventive PCI is strictly limited to the NIRS-defined lipid-rich subgroup, and how would you design a prospective trial to confirm this?
Key Response
Post-hoc analyses are highly susceptible to Type I errors due to multiple testing and often lack statistical power to formally test interaction terms (treatment x plaque phenotype). A definitive prospective, randomized trial would need to use NIRS as a stratifying variable prior to randomization to strictly prove the treatment interaction and establish true clinical utility.
If reviewing this manuscript, how would you interrogate the impact of concurrent aggressive lipid-lowering therapy on the outcomes of the non-PCI control group with lipid-rich plaques?
Key Response
A rigorous reviewer would flag that event rates in the control group might be heavily confounded by how aggressively their LDL was lowered. If the medical therapy arm was suboptimal, the relative benefit of preventive PCI might be artificially inflated. The authors must demonstrate that the PCI benefit persists even when patients are strictly adherent to contemporary, maximally tolerated lipid-lowering regimens.
Current ACC/AHA and ESC guidelines recommend intravascular imaging primarily to optimize stent deployment but do not universally mandate NIRS for plaque composition analysis to guide preventive PCI. Based on this PREVENT post hoc analysis, what level of evidence does this add, and is it sufficient to upgrade the recommendation for NIRS-guided preventive PCI?
Key Response
This post-hoc analysis generates a strong hypothesis that NIRS identifies plaques that benefit from preventive PCI, providing Level of Evidence B-NR (non-randomized/post-hoc). However, because it is post-hoc, it is likely insufficient to trigger a Class I recommendation for routine NIRS-guided preventive PCI without a dedicated prospective randomized trial, though it might justify a Class IIb recommendation for highly selected, high-risk patients.
Clinical Landscape
Noteworthy Related Trials
PROSPECT Trial
Tested
Intravascular ultrasound (IVUS) imaging of non-culprit lesions
Population
Patients presenting with acute coronary syndromes
Comparator
Observational (no direct clinical comparator)
Endpoint
Major adverse cardiovascular events (MACE) related to non-culprit lesions
COMPLETE Trial
Tested
Routine complete revascularization of non-culprit lesions
Population
Patients with STEMI and multivessel coronary artery disease
Comparator
Culprit-lesion-only PCI
Endpoint
Composite of cardiovascular death or new myocardial infarction
PROSPECT ABSORB Trial
Tested
PCI with bioresorbable vascular scaffold (BVS) plus guideline-directed medical therapy (GDMT)
Population
Patients with recent MI and non-flow-limiting vulnerable plaques
Comparator
GDMT alone
Endpoint
Minimum lumen area at 25-month follow-up
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis